XNCR Stock Summary and Trading Ideas (Xencor | NASDAQ:XNCR)

Xencor Inc is a clinical-stage biopharmaceutical company based in the United States. It focuses on discovering and developing engineered monoclonal antibody and other protein therapeutics to treat severe and life-threatening diseases such with unmet medical needs. The company uses its XmAb technology platform to create antibody product candidates such as XmAb5871 and XmAb7195. It also has a few pre-clinical stage candidates in its portfolio such as XmAb14045, XmAb662 among others. It earns its revenue from research and development collaborations and licenses of its internally developed drug candidates.

Xencor trades on the NASDAQ stock market under the symbol XNCR.

As of April 25, 2024, XNCR stock price climbed to $19.12 with 172,763 million shares trading.

XNCR has a beta of 1.24, meaning it tends to be more sensitive to market movements. XNCR has a correlation of 0.15 to the broad based SPY ETF.

XNCR has a market cap of $1.16 billion. This is considered a Small Cap stock.

Last quarter Xencor reported $45 million in Revenue and -$.31 earnings per share. This fell short of revenue expectation by $-29 million and missed earnings estimates by -$.22.

In the last 3 years, XNCR stock traded as high as $44.80 and as low as $16.49.

The top ETF exchange traded funds that XNCR belongs to (by Net Assets): IJR, VTI, XBI, VB, IWM.

XNCR has underperformed the market in the last year with a price return of -32.6% while the SPY ETF gained +23.1%. XNCR has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -3.8% and -5.7%, respectively, while the SPY returned +3.6% and -2.5%, respectively.

XNCR support price is $18.51 and resistance is $19.53 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that XNCR stock will trade within this expected range on the day.